01 March 2005
Bifenthrin activates homotypic aggregation in human T-cell lines.
Nataly Hoffman, Van Tran, Anthony Daniyan, Olutosin Ojugbele, Stephen Pryor, Josephine Bonventre, Katherine Flynn, Benjamin WeeksMed Sci Monit 2006; 12(3): BR87-94 :: ID: 447101
Abstract
Background: Here, we addressed the concern that, despite the lack of overttoxicity, exposure to low levels of the common household pyrethroid pesticide, bifenthrin, could causeharm to the immune system. To do this, we measure the effect of bifenthrin on phytohemagglutinin (PHA)activation of homotypic aggregation in human T-cell lines. Material/Methods: The human CD4+ H9, and Jurkatcell lines and the human promonocyte U937 cell line, were exposed to varying concentrations of bifenthrin.Cell viability was determined using the AlmarBlue Toxicity Assay. Concentrations of bifenthrin whichdid not reduce cell viability were determined and these concentrations were tested for the effect ofbifenthrin on PHA-mediated homotypic aggregation. Blocking antibodies to ICAM and LFA-1 were used todisrupt aggregation and a nonspecific IgG was used as a control. Results: Bifenthrin was found to benontoxic at concentrations ranging from 10[sup]-4[/sup] to 10[sup]-13[/sup] M. Bifenthrin did not inhibit PHA induced cellaggregation in all cell lines tested. However, at 10[sup]-4[/sup] M, bifenthrin to form aggregates stimulatedhomotypic aggregation in the H9 and Jurkat T-cell lines. The bifenthrin-induced aggregate formation,like that seen with PHA, was blocked by treating the cells with antibodies to either LFA-1 or ICAM. Conclusions:The results here show that bifenthrin activates T-cell function by stimulating ICAM/LFA-1 mediated homotypicaggregation. This data suggests that exposure to bifenthrin, even at "acceptable" limits, can increasethe risk for and frequency of inflammatory responses and diseases such as asthma.
Keywords: Intercellular Adhesion Molecule-1 - immunology, U937 Cells, Time Factors, T-Lymphocytes - immunology, Pyrethrins - pharmacology, Phytohemagglutinins - pharmacology, Lymphocyte Function-Associated Antigen-1 - immunology, Jurkat Cells, Cell Aggregation - immunology, Insecticides - pharmacology, Hela Cells, Dose-Response Relationship, Drug, Cell Survival - drug effects, Antibodies, Monoclonal - metabolism
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952